Ovarian cancer vaccines are under development, but none are ready for primetime. There are no screening tools for ovarian ...
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
TOP1 is the target of topotecan, which was approved in 1997 by the U.S. Food and Drug Administration (FDA) to treat relapsed ...
It’s hard to believe it was almost 20 years ago when in 2005, Patrick Dempsey originated the role of Dr. Derek Shepherd in a ...
Medpage Today on MSN4d
Adding HIPEC Boosts Survival in Recurrent Ovarian CancerThe 5-year OS rates were 46% in the HIPEC group versus 38% in the no-HIPEC group, they noted in Lancet Oncology. The trial ...
Third cohort dose is one million CAR positive cells; ten times higher than the first cohort dose . SAN JOSE, Calif., Nov. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" ...
University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...
AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...
It induces a specific type of immunity, called Th17 immunity, that seems to prevent suppression of the immune system. The ...
Researchers found significant differences in ovarian cancer survival among Asian American subgroups, emphasizing the ...
Researchers from the Walter and Eliza Hall Institute (WEHI)in Australia have found a new way to predict a subset of patients ...
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback